Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

NCT01633788

Meibomian Gland Dysfunction

COMPLETED PHASE2

The Effect of Gland Expression on the Regeneration of Meibomian Gland

NCT06163105

Meibomian Gland Dysfunction

COMPLETED NA

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

NCT04469998

Posterior Blepharitis Meibomian Gland Dysfunction

COMPLETED PHASE2

Evaluation of FID 114657 in Dry Eye Subjects

NCT01079858

Meibomian Gland Dysfunction

COMPLETED NA

Meibomian Gland Dysfunction Treatment

NCT04229888

Meibomian Gland Dysfunction Dry Eye

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meibomian Glands

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-MGD Participants

Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.

Meibum Expression

Intervention Type PROCEDURE

Meibum expression as per protocol. No investigational drug is administered in this study.

Mild-Moderate MGD Participants

Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.

Meibum Expression

Intervention Type PROCEDURE

Meibum expression as per protocol. No investigational drug is administered in this study.

Severe MGD Participants

Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.

Meibum Expression

Intervention Type PROCEDURE

Meibum expression as per protocol. No investigational drug is administered in this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Meibum Expression

Meibum expression as per protocol. No investigational drug is administered in this study.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Participants characterized as with or without Meibomian Gland Dysfunction.

Exclusion Criteria

* Lid heating therapy, therapeutic gland expression, or meibomian gland probing within 12 months of enrollment
* Contact lens use in the 30 days prior to enrollment
* Lid hygiene within 48 hours prior to enrollment
* Use of eye makeup within 8 hours of enrollment
* Eyelash growth-stimulating products within 30 days prior to enrollment
* Use of systemic vitamins and/or systemic supplements containing omega 3 fatty acids within 60 days of enrollment
* Use of systemic anti-histamines within 30 days prior to enrollment.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes